Hazard and Precautionary Statements (GHS)

Butixocort Chemical Properties,Usage,Production

Originator

Butixocort,Jouveinal

Manufacturing Process

3,20-Dione-11β-hydroxypregn-4-ene-21-thioacetate-17-butyrate (or hydrocortisone): 10.0 g (0.129 mole) of S-thioacetic acid and 220 ml of hexametapol are introduced into a reactor 27.7 ml of a 4.65 N sodium methylate methanolic solution (0.129 mole) are introduced, accompanied by stirring, at a temperature close to 20°C and then the beige solution is stirred for 1 hour at ambient temperature. Within 10 minutes, a solution of 44.0 g (0.086 mole) of cortisol-21-mesylate-17-butyrate is introduced into 440 ml of hexametapol. The solution is stirred for 2.5 hours at ambient temperature. The orange solution is precipitated in 8 liters of ice water. The insoluble substances formed are filtered and then taken up in methyl ether. The ethereal solution is extracted twice with 250 ml of 1 N sodium hydroxide solution and then three times with 500 ml of saturated sodium chloride solution. After drying the ethereal phase, the solvent is eliminated by distillation. The residue (39 g) is purified by column chromatography with the aid of 1 kg of "Florisil''. Elution by a mixture of dichloromethane and acetone 95:5 (v/v) makes it possible to collect 21 g of purified product. This product is finally recrystallized in 170 ml of a mixture of methanol and water 8:2 (v/v). Weight=19 g. Yield=44.3%. Melting point: 130°C; the structure of prepared compound is confirmed by NMR spectrum.

Therapeutic Function

Glucocorticoid